News

A professor and associate dean, Havran pursued groundbreaking immunology research that revealed key mechanisms of wound healing.

An abundance of microRNA-21 predicts lower survival in people with hard-to-treat “triple-negative” breast cancer. An innovative compound from Disney Lab awakened those cancer cells’ self-destruct system, killing the cancer cells and stopping their spread in a mouse model, while leaving healthy cells untouched.

Alda, the Emmy Award-winning actor, director and writer who has become a leading advocate for effective science communication, has partnered with Scripps Research to bring immersive communication training to scientists.

By analyzing millions of data points from wearable devices, Scripps Research scientists were able to significantly improve statewide predictions of flu epidemics.

Under a two-year contract and funding agreement, Calibr will screen its vast library of drug molecules for compounds that work against a rare but vexing family of bacteria.

Why do we remember some things for our entire lives but quickly forget others? The brain is constantly deciding which events are important enough for long-term storage.  A new study from the lab of neuroscientist Ron Davis, PhD, sheds light on one element of that process.

Mitochondrial damage is increasingly recognized as a major factor for neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and ALS. A new screening platform has identified a set of drug-like compounds that may powerfully protect mitochondria.

A drug-like compound is able to selectively prevent production of the protein underlying most causes of Parkinson’s disease, alpha-synuclein.

Chemists’ discovery of a small bacterial molecule with natural and ‘inside-out’ versions could have implications for future drug development

Scientists at Scripps Research have developed a special molecular switch that could be embedded into gene therapies to allow doctors to control dosing.

Scientists report for the first time that cerebral organoids created with cells from Alzheimer’s patients manifest excessive electrical activity just like people who have the disease.

Chemists at Scripps Research have found a new and easy route for creating an enormous variety of organic molecules for use as potential drugs or other chemical products.

A collaboration to develop new therapies for a range of diseases, including oncology, immunology, neurology and fibrosis, is announced with the goal to advance novel medicines to patients.

Topol was honored for his contributions in genomic and digital technologies to transform the practice of medicine.

The prestigious list identifies scientists who’ve disproportionately influenced their fields of research over the past decade.

Cancerous tumors often thrive because they exhaust the immune system's T cells. The new approach uncovers compounds that can restore the function of these disease-fighting cells.

New trans-Pacific chemical biology research collaboration that combines the expertise of both institutions to accelerate the pace of discovery in one of the most promising areas of science.

A discovery from Scripps Research shows that blocking the kappa opioid receptor while on a restricted-calorie diet could help shed pounds faster.

Scientists have overturned the dominant theory of how these ancient “molecular machines” are created, with insights that may lead to better medicines for a variety of diseases.

The recently discovered protein is normally abundant in fat. Without it, the body struggles to manage glucose and insulin, the scientists found.

Researchers have moved one step closer to developing an effective HIV vaccine, a major goal of medical science ever since the virus was identified in 1983.

A study led by Calibr scientists reveals that an FDA-approved cancer therapy can protect insulin-producing beta cells.  

Schimmel will receive the 2020 Kathryn C. Hach Award for Entrepreneurial Success, which honors those who have used the transforming power of chemistry to improve lives. 

A system for recycling damaged mitochondria in the brain's striatal cells normally maintains health, but it goes awry in Huntington's disease due to a protein called Rhes, a new study finds. The discovery offers a new strategy for developing treatments for Huntington's and possibly other neurodegenerative diseases that feature selective tissue loss.